ARTICLE | Product Development

Melanoma 2.0

Late-stage metastatic melanoma candidates could double survival

December 6, 2010 8:00 AM UTC

With standard of care for metastatic melanoma showing minimal success at extending lives, a recent spate of positive late-stage clinical data for a new crop of candidates could translate into a doubling of survival times for many patients.

Current drugs for metastatic melanoma are limited in their treatment effect and duration. Standard of care is dacarbazine, which was approved in the 1970s. The drug has a response rate of about 15%, progression-free survival (PFS) of 2 months and median overall survival (OS) of <8 months...